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Abstract 
Allergic rhinitis (AR) aﬀects 23–30% of the European population with equal prevalence reported in Belgium. Despite 
guidelines on the correct use of eﬀective treatment, up to 40% of AR patients remain uncontrolled. Allergen immu-
notherapy (AIT) has been shown to improve the level of control up to 84% of patients being controlled by AIT. 
Recently, new guidelines for AIT have been published, supporting the clinical evidence for eﬀectiveness of various 
subcutaneous and sublingual products for AIT in patients who are allergic to airborne allergens. AIT in AR patients not 
only reduces nasal and/or ocular symptoms but also induces tolerance and has preventive potential. Adoption of AIT 
into daily clinical practice in Belgium and other European countries is hampered primarily by reimbursement issues 
of each of the single products but also by several patient- and physician-related factors. Patients need to be better 
informed about the eﬀectiveness of AIT and the diﬀerent routes of administration of AIT. Physicians dealing with AR 
patients should inform patients on tolerance-inducing eﬀects of AIT and are in the need of a harmonized and practi-
cal guide that supports them in selecting eligible patients for AIT, in choosing evidence-based AIT products and in 
following treatment protocols with proven eﬃcacy. Therefore, a stepwise and holistic approach is needed for better 
adoption of AIT in the real-life setting in Belgium.
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Burden of allergic rhinitis
Allergic rhinitis (AR) represents one of the 3 pheno-
typic manifestations of rhinitis, besides infectious and 
non-allergic rhinitis [1, 2]. It is defined as the symp-
tomatic inflammation of the nose induced by allergen 
inhalation in sensitized individuals [3]. Clinically, AR 
is characterized by symptoms of rhinorrhea, nasal 
obstruction, sneezing and itch. AR affects 23–30% of 
patients in Europe and thereby represents the most 
common non-communicable disease [4]. A recent 
Belgian study in over 2000 participants showed aller-
gic sensitization in 40.3% of individuals with 30.9% 
also reported relevant symptoms of AR to the corre-
sponding allergen [5]. Other studies in Belgium pre-
viously showed a prevalence of self-declared allergic 
rhinitis of 29% [6, 7] mirroring the European numbers. 
Symptomatic patients experience a significant impact 
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of AR on their quality of life [8, 9]. Previous studies 
have shown that symptoms of AR significantly impact 
sleep [10], daily life [11] and in turn work productiv-
ity [12]. While missed work time (absenteeism), due 
to AR might be limited, over one-third of AR patients 
showed impaired work performance (presenteeism) 
according to a systematic analysis of 28 studies using 
the validated Work Productivity and Activity Impair-
ment (WPAI) questionnaire [13]. Another study in 
over 1000 AR patients using the Allergy Diary mobile 
application confirmed work impairment in almost all 
patients with severe symptoms [14]. Finally, rhini-
tis has been identified as a prominent risk factor of 
new-onset asthma [15, 16]. AR is associated with an 
increased risk of uncontrolled asthma (adjusted odds 
ratio of 2.0), suggesting that proper control of the 
upper airways might reduce the burden of lower air-
way diseases [17].
Socio-economic costs of AR
Because of its high prevalence in Belgium (30%) and 
Europe (23–30%), the socio-economic cost of AR is 
considerable. Total cost can be split in two catego-
ries, i.e. direct costs, which represent the expenses 
associated with medical resource utilization, and 
indirect cost, which are defined as the expenses from 
the work cessation or reduction of work productivity 
and missed opportunities in life. An American study 
revealed that AR might be the costliest disease of all 
from an employer perspective [18]. A recent EU-wide 
review showed that in Europe, avoidable indirect costs 
per patient insufficiently treated for allergy range 
between €55 and €151 billion annually due to absen-
teeism and presenteeism, corresponding to €2405 per 
untreated patient per year [19]. At the national level, 
a Swedish study estimated the total cost of AR at €1.3 
billion annually [20], with 70% of costs due to pres-
enteeism. No socio-economic studies have been con-
ducted in Belgium. Nonetheless, one may extrapolate 
these findings to the Belgian patient population.
Treatment algorithms for AR patients
Oral antihistamines alone or combined with intranasal 
corticosteroids (INS) are the cornerstone of AR treat-
ment [3, 21]. Both treatment modalities reduce AR symp-
toms and burden of disease. Lately, the combination of 
azelastine and fluticasone propionate in a nasal spray has 
demonstrated clinical eﬀectiveness along with a more 
rapid relief of symptoms when compared to INS alone in 
both adults and children with AR [22–24]. The position-
ing of these treatment modalities in relation to symptom 
severity has been published in ARIA guidelines [1, 25].
Burden of uncontrolled disease in treated AR 
patients
Despite guideline-based treatment, uncontrolled disease 
is still observed in almost one-fifth of AR patients [26]. 
A more recent study in Belgium demonstrated that 37% 
of AR patients receiving currently available pharmaco-
therapy have uncontrolled disease [27]. Real-life data col-
lected through mobile technology showed an evenly high 
percentage of patients with uncontrolled AR (unpub-
lished data Allergy Diary). Diﬀerent disease-, diagnosis-, 
patient- and treatment-related factors might be account-
able for the high burden of uncontrolled disease [28, 29]. 
Remarkably, the prevalence of uncontrolled disease was 
only 16% in AR patients 3 years after initiation of subcu-
taneous allergen immunotherapy (AIT) [27]. This real-life 
study also showed that only 15% of AR patients attending 
a tertiary referral center for AR received AIT, illustrating 
the need for better adoption of AIT in daily practice.
Three key milestones for AIT adoption have been iden-
tified and will be addressed here (Fig. 1). The first require-
ment relates to the clinical evidence on the treatment 
eﬀectiveness and safety of AIT. The second requirement 
relates to the demonstration of cost-eﬀectiveness—and 
thus health economic impact—of AIT, subsequently jus-
tifying reimbursement of the provided therapy. Finally, 
the third requirement relates to overcoming real-life bar-
riers that impede AIT adoption in daily practice.
Clinical evidence for AIT in the treatment of AR 
patients
According to an explorative patient survey conducted 
amongst newly diagnosed AR patients, 40% percent of 
Belgian AR patients expect a treatment that cures their 
Fig. 1 AIT adoption pyramid for real-life implementation
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disease [30]. AIT aims at inducing immunological toler-
ance and it is the only therapy for AR patients with dis-
ease modifying capacity [31]. In the ARIA guidelines, 
AIT is currently positioned as an additional treatment 
option for patients with uncontrolled disease despite 
adequate pharmacotherapy [25]. Both subcutaneous and 
sublingual immunotherapy (SCIT and SLIT) are available 
and the selection of the optimal therapeutic approach 
depends on the patients’ phenotype and endotype [32], 
the patients’ preference for SCIT or SLIT [30], the avail-
ability of specific AIT products with proven eﬃcacy [33], 
and the (lack of ) reimbursement of AIT [34].
Clinical evidence of AIT eﬀectiveness and safety 
for allergic rhinoconjunctivitis was recently reviewed 
according to the Appraisal of Guidelines for Research 
and Evaluation (AGREE II) approach and resulted in a 
guideline document published by the European Academy 
for Allergy and Clinical Immunology (EAACI) [33, 35]. 
Meta-analysis of randomized controlled trials indicated 
that both SCIT and SLIT are eﬀective for seasonal and 
perennial AR for its short-term benefit. Both are associ-
ated with reductions in symptoms and medication use. A 
treatment period of 3 years is recommended to achieve 
long-term eﬃcacy persisting after treatment discontinu-
ation. Recently, real-life evidence of birch-pollen AIT 
studies underlined the potential of AIT to induce long-
term eﬀects [31]. These studies showed reduced intake of 
AR and asthma medication and decreased risk of new-
onset asthma medication use 6  years after cessation of 
AIT. Thus, broad evidence for the clinical eﬃcacy of AIT 
has been demonstrated for AR but product-specific eval-
uation of evidence-based eﬀectiveness is recommended 
[33].
In addition to the beneficial eﬀect on nasal and ocular 
symptoms AIT has also been propagated for its eﬀects on 
lower airways symptoms. A systematic review and meta-
analysis led by an EAACI Task Force on AIT for allergic 
asthma concluded that substantial reductions in short-
term symptom and medication scores were observed 
after AIT treatment [36]. More studies are needed to 
investigate the long-term eﬀects on asthma. A recent 
study performed in children with grass pollen allergy 
demonstrated the potential of SLIT to prevent asthma 
symptoms and reducing asthma medication at 2 years of 
post-treatment follow-up [37]. More evidence is however 
needed to evaluate the preventive capacities of AIT in 
children, both with regard to development of new sensiti-
zations as well as disease progression.
Finally, both SCIT and SLIT are safe and well-tolerated 
therapies when correctly applied [33]. SCIT injections 
should be given in a medical setting by experienced per-
sonnel trained in the early recognition and management 
of systemic reactions. A 4-year real-life US survey that 
included over 23.3 million injection visits reported sys-
temic reactions in 0.1% of cases [38]. Systemic reactions 
with SLIT appear to be very unlikely although the over-
all rate of adverse reactions is similar between SCIT and 
SLIT. Other side eﬀects include local reactions at the skin 
(redness, itching or swelling for SCIT), mouth (mucosal 
reactions for SLIT) or abdomen (abdominal pain for 
SLIT). Most of these reactions however occur during the 
initial phase of the treatment course and are considered 
to be of mild intensity and self-limiting [33].
Evidence for cost-effectiveness of AIT in AR 
patients
Symptomatic treatment accounts for an important part 
of the direct and indirect costs of AR. Because of their 
sedating eﬀects, first generation antihistamines impair 
mental performances of AR patients [39], thereby 
increasing indirect costs. Second generation antihista-
mines and intranasal antihistamines are eﬀective and 
safe, without changing the course of the disease. INS are 
eﬀective in reducing most of AR symptoms [40] but a sig-
nificant number of patients fear adverse events [30].
The socio-economic evaluation of AIT needs to be 
seen in the context of cost savings caused by decreased 
consumption of symptomatic drugs, fewer visits to the 
GP and specialist, and increased work productivity. The 
2010 revision of the ARIA guidelines called for further 
studies on the cost-eﬀectiveness of AIT [21]. The qual-
ity-adjusted life-year (QALY) is a valuable health metric 
that encompasses the impact on both quantity and qual-
ity of life and is used to evaluate the cost-eﬀectiveness of 
novel therapies. In a systematic review in 2017 funded by 
the EU, Asaria and coworkers have elegantly examined 
the cost-eﬀectiveness studies of SLIT and SCIT versus 
standard care using QALY [41]. Nineteen studies from 
14 European countries were analyzed (Germany, Den-
mark, Italy, UK, Austria, Finland, France, Sweden, the 
Netherlands, Canada, Czech Republic, Norway, Spain). 
Results from this systematic analysis revealed that both 
SLIT and SCIT can be considered as cost-eﬀective in AR 
patients (with or without asthma) using the cost-eﬀec-
tiveness threshold of £20,000 (about €22 000) per QALY 
(as defined by the UK National Institute for Health and 
Care Excellence (NICE) [42], responsible for assessing 
health technology value for the National Health Service 
(NHS)). It is worth noting that discrepancies in terms of 
absolute values were observed between countries (due 
to the healthcare system in place), but all studies were 
below the threshold of €22 000 per QALY. Despite the 
economic evidence of cost-eﬀectiveness, AIT is currently 
reimbursed in 56% of European countries (full reim-
bursement: 32% and partial reimbursement: 24%) [34]. In 
Belgium there is no reimbursement yet, which represents 
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an obstacle towards immunotherapy adoption in clinical 
practice.
Overcoming real-life barriers for AIT 
implementation in real-life
The first and second milestones for AIT adoption have 
been met, i.e. evidence for clinical eﬃcacy and cost-eﬀec-
tiveness, through various European and Belgian studies. 
A consensus meeting organized by the National Institute 
for Health and Disability Insurance in Belgium (i.e. Rijk-
sinstituut voor ziekte- en invaliditeitsverzekering, RIZIV) 
similarly concluded that suﬃcient clinical eﬀectiveness is 
available and that cost-eﬀectiveness is likely to be present 
after a minimal treatment with AIT of 3 years, especially 
given the reduction of other medical treatments and the 
long-term eﬀects after cessation of the AIT [43].
Adoption of AIT in daily practice represents an addi-
tional and equally important milestone that requires 
relentless implementation focus, ultimately leading to 
better control of disease and prevention of asthma. The 
real-life barriers towards adoption of AIT in Belgium 
have been previously assessed in a nationwide survey 
amongst Ear-Nose-Throat (ENT) specialists and showed 
that the 2 main reasons for not prescribing AIT were lack 
of expertise by health care professionals (HCPs) and per-
ception of high costs associated with AIT [44]. The latter 
barrier should be overcome by reimbursement of AIT in 
Belgium. Increasing the expertise and awareness on AIT 
requires education of physicians on how to select eligible 
patients for AIT, when to prescribe AIT, what product to 
prescribe and what protocol to follow, and how to follow 
up patients on AIT. Figure 2 summarizes 4 key challenges 
in care delivery for AR patients and the strategies to over-
come these challenges in the context of improving the 
adoption of AIT in real-life.
The first challenge for adopting AIT in practice is 
to provide better, faster and more timely access of AR 
patients to the right treatment, including AIT. As such 
the burden of uncontrolled disease might be reduced and 
the preventive potential for asthma becomes reality. In 
that perspective, patients and HCPs need to be informed 
about the newest data on the eﬃcacy and preventive 
potential of AIT, which will lead to increased aware-
ness and hence will accelerate adequate diagnosis, early 
detection of good candidates for AIT, and timely referral 
to HCPs with specific interest in AIT. Patient Awareness 
Programs seem essential in order to improve patient and 
physician awareness. Interestingly, a nationwide multi-
stakeholder public health campaign in Finland, so called 
‘Finnish Allergy Program’ has been successfully imple-
mented. Intermediate analysis after 5 years demonstrated 
clear improvements in clinical as well as health-economic 
outcomes of AR treatment [45]. On top of that, digi-
tal solutions, such as the Allergy Diary App and Patient 
E-Learning platforms can now be used in such cam-
paigns as AR self-assessment tools to increase awareness 
but also to measure success of the campaign itself.
The second challenge for adopting AIT in practice 
can be overcome by following the AR guidelines and 
by increasing the adherence to AIT. In that perspec-
tive, global standardization, simplification and a more 
Fig. 2 Overcoming real-life barriers for AIT adoption. AR: allergic rhinitis, CDSS: clinical decision support system, HCPs: health care professionals, ICP: 
integrated care pathway
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impactful implementation of AIT guidelines might be 
required, through practical education of physicians. Sec-
ondly, a drastic improvement of medication adherence is 
required and can be pursued through leverage of remote 
patient coaching and digital solutions [46]. Digital Tools, 
such as Clinical Decision Support Systems (CDSS) [47, 
48] might be eligible to support HCPs in the adoption 
and application of AIT guidelines.
The third challenge relates to the need for real-life evi-
dence on the impact of AIT on the quality of life and work 
productivity of AR patients. Continuous and remote 
monitoring of patients by digital technology will create 
big data on patient outcomes and can serve as a source 
for real-life evidence on AIT eﬀects on AR (burden of 
AR and its comorbidities, impact of AIT, health-eco-
nomic impact on AIT). Continuous monitoring further-
more enables a proactive and personalized approach of 
HCPs prior to and throughout the treatment and allows 
exchange of best practice protocols between HCPs. Addi-
tionally, it will also make sure we will better understand 
why patients respond to AIT and others don’t.
The fourth and last challenge relates to the day-to-day 
delivery of care. Optimization of the full care pathway of 
the patients can be achieved via better transmural (1st, 
2nd and 3rd line of care) and multi-disciplinary (allergol-
ogy, ENT, pulmonology, pediatrics) collaboration, which 
forms the basis of an integrated care pathway for patients 
with allergic rhinitis with or without asthma [49]. Conse-
quently, this ensures that the right patient is exposed to 
the right therapy (in this case AIT) at the right moment. 
Moreover, it significantly improves eﬃciency, through a 
shorter length of the entire pathway, alignment on neces-
sary and priority patient visits, and improved utilization 
of infrastructure.
Conclusion and recommended next steps
Clinical eﬃcacy and safety data support the recommenda-
tion of SCIT and SLIT for use in patients with AR. How-
ever, physicians should look into product-specific evidence 
before prescribing AIT to patients and they should follow 
treatment protocols for AIT products with proven eﬃcacy. 
Health-economic evaluation in Europe has provided evi-
dence for cost-eﬀectiveness of AIT. However, cost-eﬀec-
tiveness evaluation studies in Belgium are lacking and are 
needed to move forward towards better implementation 
and reimbursement of AIT in Belgium. Further adoption 
of AIT into daily practice will require a stepwise approach 
with active engagement of all stakeholders involved across 
the full care pathway of the AR patient (Fig. 3). The subse-
quent steps which are required are listed here.
Step 1
Reimbursement of specific AIT products in Belgium. 
Reimbursement procedures however might take time. 
The eﬀects of adoption of in practice (steps 2–6) will 
grow once step 1 is met but should be initiated as soon 
as possible.
Step 2
Develop and disseminate a simple AIT Pocket Guide for 
physicians to better understand and prescribe AIT.
Fig. 3 ARIA-EUFOREA implementation strategy for AIT adoption. ICP: integrated care pathway
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Step 3
Provide practical and evidence-based education for phy-
sicians through national or regional Workshops or Mas-
terclasses for change management in AIT.
Step 4
Implement Integrated Care Pathways supported by the 
development and deployment of a Clinical Decision Sup-
port System (CDSS).
Step 5
Implement a national registry for AIT in hospitals and 
private allergy clinics.
Step 6
Deploy Patient Awareness Programs based on self-man-
agement proposals of next-generation care pathways 
including ARIA-EUFOREA educational materials.
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